$1.32
-0.01 (-0.75%)
Open$1.32
Previous Close$1.33
Day High$1.33
Day Low$1.29
52W High$4.35
52W Low$1.01
Volume—
Avg Volume58.1K
Market Cap34.61M
P/E Ratio—
EPS$-3.33
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+840.9% upside
Current
$1.32
$1.32
Target
$12.42
$12.42
$7.12
$12.42 avg
$14.14
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 70.84M | 51.91M | 10.25M |
| Net Income | -75,634,132 | -49,879,621 | 2.27M |
| Profit Margin | -106.8% | -101.4% | 22.1% |
| EBITDA | -65,592,862 | -45,660,745 | 3.06M |
| Free Cash Flow | — | — | 1.07M |
| Rev Growth | +36.5% | +36.5% | +24.9% |
| Debt/Equity | 4.75 | 4.75 | 0.86 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |